Profile: GlaxoSmithKline PLC (GSK)
15 Nov 2018
GlaxoSmithKline plc, incorporated on December 6, 1999, is a global healthcare company. The Company operates through three segments: Pharmaceuticals, Vaccines and Consumer Healthcare. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company develops a range of prescription medicines, vaccines and consumer healthcare products.
The Company's medicines portfolio products include Adartrel, Bactroban, Ceftin, Daraprim, Eumovate, Flixonase, Imigran, Jalyn, Lamictal, Malarone, Naramig, Otosporin ear drops, Pentostam, Relenza, Seretide, Tracrium, Ultiva, Valtrex, Wellbutrin and Zantac. Its vaccines portfolio products include Ambirix, Bexsero, Cervarix, Encepur, Fendrix, Havrix, Infanrix, Kinrix, Menhibrix, Pandemrix, Quinvaxem, Rabipur, Synflorix, Twinrix and Varilrix. Its consumer healthcare products are categorized as pain relief, oral health, respiratory, nutrition/gastro intestinal and skin health. Its pain relief product category includes brands, such as Voltaren, Panadol and Excedrin. Its oral health product category includes brands, such as sensodyne, parodontax, polident, biotene and aquafesh. Its respiratory product category includes brands, such as Flonase, contac and smoker's health-nicotinell. Its nutrition/gastro intestinal product category includes brands, such as Horlicks, Eno and Tums. Its skin health product category includes brands, such as physiogel, abreva, zovirax, Lamisil and fenistil.
The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. It focuses its research across respiratory, HIV and infectious diseases, immuno-inflammation, oncology and rare diseases. It provides a range of inhaled respiratory products, including Nucala (mepolizumab) and its Ellipta portfolio. Its global HIV business is managed through ViiV Healthcare. Its specialty products portfolio includes medicines, such as Benlysta, a treatment for lupus disease, and Tanzeum/Eperzan, for Type II diabetes. Its classic and established products include over 400 post-patent medicines in the areas of anti-infectives, allergy, neurosciences, dermatology, respiratory and urology.
The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It delivers over two million vaccine doses per day to people living in over 160 countries. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines that offer protection against over 20 different diseases. These include Bexsero, its meningitis B vaccine; Menveo for meningitis A, C, W and Y; Flu; Hepatitis; Synflorix for pneumococcal disease; Rotarix for rotavirus gastroenteritis; and vaccines against diphtheria, tetanus and whooping cough, namely, Infanrix/Pediarix and Boostrix. The Consumer Healthcare business develops and markets products in wellness, oral health, nutrition and skin health categories. Its brands include Otrivin, Panadol, parodontax, Poligrip, Sensodyne, Theraflu and Voltaren. Its nutrition business includes Horlicks. Its skin health brands include Abreva and Zovirax.
980 Great West Road
BRENTFORD TW8 9GS
Company Web Links
- GSK feels shingles vaccine boost, but shares slip on drugs mix
- UPDATE 3-GSK feels shingles vaccine boost, but shares slip on drugs mix
- GSK beats Q3 forecasts on strong Shingrix sales, nudges up guidance
- UK Stocks-Factors to watch on Oct 31
- Long-lasting HIV injection is a step closer after second GSK study